Evaluation of the Tg.AC Transgenic Mouse Assay for Testing the Human Carcinogenic Potential of Pharmaceuticals—Practical Pointers,Mechanistic Clues,and New Questions
Free accessResearch articleFirst published online January, 2002
Evaluation of the Tg.AC Transgenic Mouse Assay for Testing the Human Carcinogenic Potential of Pharmaceuticals—Practical Pointers,Mechanistic Clues,and New Questions
Transgenic mouse strains with genetic alterations known to play a role in the multistage process of carcinogenesis are being used increasingly as models for evaluating the human carcinogenic potential of chemicals and Pharmaceuticals. The Tg.AC transgenic mouse is one of the strains currently being used in such alternative short-term carcinogenicity testing protocols. This review is focused on recent data from studies designed to evaluate this model's ability to discriminate carcinogens from noncarcinogens. Details relating to protocol design that can significantly impact study outcome are described. Data relating to mechanisms of chemical tumor induction in the Tg.AC model are reviewed, and questions have been formulated to encourage research to further guide appropriate future applications of this model.
Akgun, E., J. Zahn, S. Baumes, G. Brown, F. Liang, P. J. Romanienko, S. Lewis, and M. Jasin.1997. Palindromic resolution and recombination in the mammalian germ line. Mol. Cell Biol.17:559–570.
2.
Albert, R. E., J. E. French, R. Maronpot, J. Spalding, and R. Tennant.1996. Mechanism of skin tumorigenesis by contact sensitizers: The effect of the corticosteroid fluocinolone acetonide on inflammation and tumor induction by 2,4 dinitro-1-fluorobenzene in the skin of the TG.AC (v-Ha-ras) mouse. Environ. Health Perspect.104:1062–1068.
3.
Balmain, A., M. Ramsden, G. T. Bowden, and J. Smith.1984. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature307:658–660.
4.
Battalora, M. S., J. W. Spalding, C. J. Szczesniak, J. E. Cape, R. J. Morris, C. S. Trempus, C. D. Bortner, B. M. Lee, and R. W. Tennant.2001. Age-dependant skin tumorigenesis and transgene expression in the Tg.AC (v-Ha-ras) transgenic mouse. Carcinogenesis22:651–659.
5.
Bell, A.C., and G. Felsenfeld.1999. Stopped at the border: Boundaries and insulators. Curr. Opin. Genet. Dev.9:191–198.
6.
Bhat, H. K., X. Han, A. Gladek, and J. G. Liehr.1994. Regulation of the formation of the major diethylstilbestrol-DNA adduct and some evidence of its structure. Carcinogenesis15:2137–2142.
7.
Blanchard, K. T., D. J. Ball, J. E. Holden, S. M. Furst, J. H. Stoltz, and R. E. Stoll.1998. Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12–0-tetradecanoy 113-acetate (TPA) and benzene. Toxicol. Pathol.26:541–547.
8.
Bos, J. L.1998. All in the family? New insights and questions regarding interconnectivity of ras, rap1 and ral. EMBO J.17:6776–6782.
9.
Brayton, C.F.1986. Dimethyl sulfoxide(DMSO): A review. Cornell Vet.76:61–90.
10.
Brown, K., M. Quintanilla, M. Ramsden, I. B. Kerr, and A. Balmain.1986. v-Ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. Cell46:447–456.
11.
Cannon, R. E., J. W. Spalding, K. M. Virgin, R. S. Faircloth, M. C. Humble, G. D. Lacks, and R. W. Tennant.1998. Induction of transgene expression in Tg.AC (v-Ha-ras) transgenic mice concomitant with DNA hypomethylation. Mol. Carcinog.21:244–250.
12.
Cardiff, R. D., A. Leder, A. Kuo, P. K. Pattengale, and P. Leder.1993. Multiple tumor types appear in a transgenic mouse with the RAS oncogene. Am. J. Pathol.142:1199–1207.
13.
Cavalieri, E., K. Frenkel, J. G. Liehr, E. Rogan, and D. Roy.2000. Estrogens as endogenous genotoxic agents—DNA adducts and mutations. J. Natl. Cancer Inst. Monogr.75–93.
14.
Cerutti, P. A., and B. F. Trump.1991. Inflammation and oxidative stress in carcinogenesis. Cancer Cells3:1–7.
15.
Chen, Y., L. C. Megosh, S. K. Gilmour, J. A. Swaicki, and T. G. O'Brien.2000. K6/ODC transgenic mice as a sensitive model for carcinogen detection. Toxicol. Lett.116:27–35.
16.
Collick, A., J. Drew, J. Penberth, P. Bois, J. Luckett, F. Scaerou, A. Jeffreys, and W. Reik.1996. Instability of long inverted repeats within mouse transgenes. EMBO J.15:1163–1171.
17.
Delker, D. A., B. L. Yano, and B. B. Gollapudi.1999. V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury. Toxicol. Sci.50:90–97.
18.
Eastin, W. C., J. K. Haseman, J. F. Mahler, and J. R. Bucher.1998. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol. Pathol.26:461–473.
19.
Eastin, W. C., J. H. Mennear, R. W. Tennant, R. E. Stoll, D. G. Branstetter, J. R. Bucher, B. McCullough, R. L. Binder, J. W. Spalding, and J. F. Mahler.2001. Tg.AC genetically altered mouse: Assay working group overview of available data. Toxicol. Pathol.29(Suppl.):60–80.
20.
Federal Register.1996. Testing for carcinogenicity of Pharmaceuticals. Number 43298.
21.
Fischer, S. M.1985. Arachidonic acid metabolism and tumor promotion. In Arachidonic acid metabolism and tumor promotion, ed. S. Fischer and T. Slaga, 21–47. Boston, MA: Martinus Nijohoff.
22.
French, J.E., and M. Saulnier.2000. Benzene leukemogenesis: An environmental carcinogen-induced tissue-specific model of neoplasia using genetically altered mouse models. J. Toxicol. Environ. Health Part A61:377–379.
23.
Friedman, O. M., A. Myles, and M. Colvin.1979. Cyclophosphamide and related phorphoramide mustards, current status and future prospects. Adv. Cancer Chemother.1:143–204.
24.
Furstenberger, G., and F. Marks.1983. Growth stimulation and tumor promotion in skin. J. Invest. Dermatol.81(1S):157S–162S.
25.
Hansen, L.A., and R. Tennant.1994a. Follicular origin of epidermal papillomas in v-Ha-ras-transgenic Tg.AC mouse skin. Proc. Natl. Acad. Sci. USA87:7822–7826.
26.
Hansen, L. A., and R. Tennant.1994b. Focal transgene expression associated with papilloma development in v-Ha-ras-transgenic Tg.AC mice. Mol. Carcinog.9:143–154.
27.
Hansen, L. A., C. S. Trempus, J. F. Mahler, and R. W. Tennant.1996. Association of tumor development with increased cellular proliferation and transgene overexpression, but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice. Carcinogenesis17:1825–1833.
28.
Henikoff, S. 1998. Conspiracy of silence among repeated transgenes. BioEssays20:532–535.
29.
Holden, H. I., R. E. Stoll, and K. T. Blanchard.1999. Oxymetholone: II. Evaluation in the Tg.AC transgenic mouse model for detection of carcinogens. Toxicol. Pathol.27:507–512.
30.
Honchel, R., B. A. Rosenzweig, K. L. Thompson, K. T. Blanchard, S. M. Furst, R.E. Stoll, and F. D. Sistare.2001. Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype. Mol. Carcinog.30:99–110.
31.
Humble, M. C., N. Kouprina, V. N. Noskov, J. Graves, E. Garner, R. W. Tennant, M. A. Resnick, V. Larionov, and R. E. Cannon.2000. Radial transformation-associated recombination cloning from the mouse genome: Isolation of Tg.AC transgene with flanking DNAs. Genomics70:292–299.
32.
International Agency for Research on Cancer. 1987. Overall evaluations of carcinogenicity: An updating of IARC Monographs, vol. 1 to 42, suppl. 7. Lyon, France: IARC.
33.
Isaka, H., H. Yoshii, A. Otsuji, M. Koike, Y. Nagai, M. Koura, K. Sugiyasu, and T. Kanabayashi.1979. Tumors of Spraque-Dawley rats induced by long-term feeding of phenacetin. Gann70:29–36.
34.
Jacoby, W. T., and H. S. Weiss.1986. Inhibition and enhancement of skin tumors in mice by dimethyl sulfoxide depending on method of application. J. Natl. Cancer Inst.77:983–987.
35.
Jarman, A. P., W. G. Wood, J. Sharpe, G. Gourdon, H. Ayyub, and D. R. Higgs.1991. Characterization of the major regulatory element upstream of the human α-globin gene cluster. Mol. Cell Biol.11:4679–4689.
36.
Klein, C. B., and M. Costa.1997. DNA methylation, heterochromatin, and epigenetic carcinogens. Mutat. Res.386:163–180.
37.
Laverriere, A. C., C. MacNeill, C. Mueller, R. E. Poelmann, J. B. E. Burch, and T. Evans.1994. GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J. Biol. Chem.269:23177–23184.
38.
Leach, D. R. F.1994. Long DNA palindromes, cruciform structures, genetic instability and secondary structure repair. BioEssays16:893–900.
39.
Leder, A., A. Kuo, R. D. Cardiff, E. Sinn, and P. Leder.1990. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA87:9178–9182.
40.
Mahler, J. F., N. D. Flagler, D. E. Malarkey, P. C. Mann, J. K. Haseman, and W. Eastin.1998. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol. Pathol.26:501–511.
41.
Mahler, J. F., W. Stokes, P. Mann, M. Takaoka, and R. P. Maronpot.1996. Spontaneous lesions in aging FVB/N mice. Toxiol. Pathol.24:710–716.
42.
Marian, B. 1987. Tumor-promoting phorbol esters cause a stable reduction of dermal collagen in mouse skin. Eur. J. Cancer Clin. Oncol.23:1035–1039.
43.
Maronpot, R. R., T. Fox, D. E. Malarkey, and T. Goldsworthy.1995. Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology101:125–156.
44.
Marquardt, P. 1970. Experimentell Untersuchungen über carcinogene wirkungen von Krebs-chemotherapeutic a un immunosuppresiva. Arnz. Fors.20:1461–1467.
45.
Merika, M., and S. H. Orkin.1995. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Kruppel family proteins Sp1 and EKLF. Mol. Cell Biol.15:2437–2447.
46.
Miller, D. R., D. P. Allison, M. C. Rorvik, and T. J. Slaga.1991. Inhibited morphological terminal differentiation and enhanced proliferation of cultured mouse epidermal cells at different concentrations of dimethyl sulfoxide. Cell Prolif.24:191–210.
47.
Morimoto, T., K. Hasegawa, S. Kaburagi, T. Kakita, H. Wada, T. Yanazume, and S. Sasayama.2000. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J. Biol. Chem.275:13721–13726.
48.
Moser, G. J., C. S. Trempus, J. F. Mahler, S. M. Ward, R. Wilson, M. Streicker, R. R. Tice, T. L. Goldsworthy, and R. W. Tennant.2001. Topical exposure of v-Ha-ras Tg.AC mcie to the insecticide rotenone. Toxicologist60:278.
49.
Nakanishi, K., Y. Kurata, M. Oshima, S. Fukushima, and N. Ito.1982. Carcinogenicity of phenacetin: Long-term feeding study in B6c3f1 mice. Int. J. Cancer29:439–444.
50.
National Toxicology Program. 1978a. Bioassay of p-anisidine for possible carcinogenicity (CAS No. 20265–97-8). Technical Report Series No. 116. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
51.
National Toxicology Program. 1978b. Bioassay of pyrimethamine for possible carcinogenicity (CAS No. 58–14–0). Technical Report Series No. 77. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
52.
National Toxicology Program. 1979a. Bioassay of p-cresidine for possible carcinogenicity (CAS No. 120–71–8). Technical Report Series No. 142. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
53.
National Toxicology Program. 1979b. Bioassay of 2,4-diaminotoluene for possible carcinogenicity (CAS No. 95–80–7). Technical Report Series No. 162. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
54.
National Toxicology Program. 1979c. Bioassay of sulfisoxazole for possible carcinogenicity (CAS No. 127–69–5). Technical Report Series No. 138. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
55.
National Toxicology Program. 1980a. Bioassay of 2,6-toluenediamine dihydrochloride for possible carcinogenicity (CAS No. 15481–70–6). Technical Report Series No. 200. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
56.
National Toxicology Program. 1980b. Bioassay of phenol for possible carcinogenicity (CAS No. 108–95–2). Technical Report Series No. 203. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
57.
National Toxicology Program. 1982a. Carcinogenesis bioassay of 2,3,7,8-tetrachlorodibenzo-p-dioxin (CAS No. 1746–01–6) in Osborne-Mendel rats and B6C3F1 mice (gavage study). Technical Report Series No. 209. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
58.
National Toxicology Program. 1982b. Carcinogenesis bioassay of di(2-ethylhexyl)phthalate (CAS No. 117–81–7) in F344 rats and B6C3F1 mice (feed studies). Technical Report Series No. 217. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
59.
National Toxicology Program. 1982c. Bioassay of reserpine for possible carcinogenicity (CAS No. 50–55–5). Technical Report Series No. 193. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
60.
National Toxicology Program. 1985a. Toxicology and carcinogenesis studies of 8-hydroxyquinoline (CAS No. 148–24–3) in F344/N rats and B6C3F1 mice (feed studies). Technical Report Series No. 276. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
61.
National Toxicology Program. 1985b. Toxicology and carcinogenesis studies of 2-chloroethanol (CAS No. 107–07–3) in F344/N rats and Swiss CD-1 mice (dermal studies). Technical Report Series No. 275. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
62.
National Toxicology Program. 1986a. Carcinogenesis studies of ethyl acrylate (CAS No. 140–88–5)in F344/N rats and B6C3F1 mice (gavage studies). Technical Report Series No. 259. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
63.
National Toxicology Program. 1986b. Toxicology and carcinogenesis studies of benzene (CAS No. 71–43–2) in F344/N rats and B6C3F1 mice (gavage study). Technical Report Series No. 289. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
64.
National Toxicology Program. 1986c. Toxicology and carcinogenesis studies of dimethylvinyl chloride (CAS No. 513–37–1) in F344/N rats and B6C3F1 mice (gavage studies). Technical Report Series No. 316. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
65.
National Toxicology Program. 1988. Toxicology and carcinogenesis studies of rotenone (CAS No. 83–79–4) in F344/N rats and B6C3F1 mice (feed studies). Technical Report Series No. 320. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
66.
National Toxicology Program. 1990. Toxicology and carcinogenesis studies of glycidol (CAS No. 556–52–5) in F344/N rats and B6C3F1 mice (gavage studies). Technical Report Series No. 374. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
67.
National Toxicology Program. 1992. Toxicology and carcinogenesis studies of resorcinol (CAS No. 108–46–3) in F344/N rats and B6C3F1 mice (gavage studies). Technical Report Series No. 403. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
68.
National Toxicology Program. 1994. Toxicology and carcinogenesis studies of o-benzyl-p-chlorophenol (CAS No. 120–32–1) in F344/N rats and B6C3F1 mice (gavage studies). Technical Report Series No. 424. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
69.
National Toxicology Program. 1995a. Initiation/promotion study of o-benzyl-p-chlorophenol (CAS No. 120–32–1) in Swiss (CD-1) mice (mouse skin study). Technical Report Series No. 444. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
70.
National Toxicology Program. 1995b. Toxicology and carcinogenesis studies of benzethonium chloride (CAS No. 121–54–0) in F344/N rats and Swiss CD-1 mice (dermal studies). Technical Report Series No. 438. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
71.
National Toxicology Program. 1996. Comparative initiation/promotion studies of B6C3F1 mice, Swiss (CD-I) mice, and sencar mice. Technical Report Series No. 441. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
72.
National Toxicology Program. 1998. Toxicology and carcinogenesis studies of 1-chloro-2-propanol (CAS No. 127–00–4) in F344/N rats and B6C3F1 mice (drinking water studies). Technical Report Series No. 477. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
73.
National Toxicology Program. 1999a. Toxicology and carcinogenesis studies of oxymetholone (CAS No. 434–07–1) in F344/N rats and toxciology studies of oxymetholone in B6C3F1 mice (gavage studies). Technical Report Series No. 485. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
74.
National Toxicology Program. 1999b. Toxicology and carcinogenesis studies of oleic acid diethanolamine (CAS No. 93–83–4) in F344/N rats and B6C3F1 mice (dermal studies). Technical Report Series No. 481. U.S. Department of Health and Human Services, Public Health Service, Bethesda, Maryland.
75.
Nylander-French, L. A., and J. E. French.1998. Tripropylene glycol diacrylate but not ethyl acrylate induces skin tumors in a twenty-week short-term tumorigenesis study in Tg.AC (v-Ha-ras) mice. Toxicol. Pathol.26:476–483.
76.
O'Brien, T. G., L. C. Megosh, G. Gilliard, and A. P. Soler.1997. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res.57:2630–2637.
77.
Oosterwegel, M., J. Timmerman, J. Leiden, and H. Clever.1992. Expression of GATA-3 during lymphocyte differentiation and mouse embryogenesis. Deve. Immunol.3:1–11.
78.
Orkin, S. H.1992. GATA-binding transcription factors in hematopoietic cells. Blood80:575–581.
79.
Owens, D. M., J. W. Spalding, R. W. Tennant, and R. C. Smart.1995. Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in Tg.AC transgenic mouse skin. Cancer Res.55:3171–3178.
80.
Palmiter, R. D., and R. L. Brinster.1986. Germ-line transformation of mice. Ann. Rev. Genet.20:465–499.
81.
Physicians' Desk Reference.51st ed., 1997. Montvale, NJ: Medical Economics.
82.
Pondel, M. D., J. A. Sharpe, S. Clark, L. Pearson, W. G. Wood, and N. J. Proudfoot.1996. Proximal promoter elements of the human zeta-globin gene confer embryonic-specific expression on a linked reporter gene in transgenic mice. Nucleic Acid Res.24:4158–4164.
83.
Ptashne, M. 1988. How eukaryotic transcriptional activators work. Nature335:683–689.
84.
Reddy, J. K., M. S. Rao, D. L. Azarnoff, and S. Sell.1979. Mitogenic and carcinogenic effects of hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinlythio]acetic acid (Wy-14,643) in rat and mouse liver. Cancer Res.39:152–161.
85.
Robinson, D. 1998. The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol. Pathol.26:474–475.
86.
Roberts, A. B., and M. B. Sporn.1984. Cellular biology and biochemistry of the retinoids. In The retinoids, vol. 2, 209–286. San Diego: Academic Press.
87.
Sabath, D. E., E. A. Spangler, E. M. Rubin, and G. Stamatoyannopoulos.1993. Analysis of the human zeta-globin gene promoter in transgenic mice. Blood82:2899–2905.
88.
Sabath, D. E., K. M. Koehler, W.-Q., Yang, K. Patton, and G. Stamatoyannopoulos.1995. Identification of a major positive regulatory element located 5′ to the human zeta-globin gene. Blood85:2587–2597.
89.
Sabath, D. E., K. M. Koehler, W.-Q. Yang, V. Phan, and J. Wilson.1998. DNA-protein interactions in the proximal α-globin promoter: Identification of novel CCACCC-and CCAAT-binding proteins. Blood Cells. Mol. Dis.24:183–198.
90.
Shimomura, M., S. Higashi, and R. Mizumoto.1992. 32P-postlabeling analysis of DNA adducts in rats during estrogen-induced hepatocarcinogenesis and effect of tamoxifen on DNA adduct level. Jpn. J. Cancer Res.83:438–444.
91.
Sistare, F. D., L. Anderson, J. F. Contrera, et al. 1997. A preliminary evaluation of the Tg.AC transgenic mouse model for carcinogenicity testing. In Molecular toxicology: Utilization in accelerated drug discovery and chemical safety analysis, ed. P. Guttry, 39–60, Southbridge, MA: IBC Library Series, International Business Comunications.
92.
Slaga, T. J., and S. M. Fischer.1983. Strain differences and solvent effects in mouse skin carcinogenesis experiments using carcinogens, tumor initiators and promoters. Prog. Exp. Tumor Res.26:85–109.
93.
Smith, M. K., C. S. Trempus, and S. K. Gilmour.1998. Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin. Carcinogenesis19:1409–1415.
94.
Spalding, J. W., J. E. French, S. Stasiewicz, M. Furedi-Machacek, F. Conner, R. R. Tice, and R. W. Tennant.2000. Response of transgenic mouse lines p53+/–and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol. Sci.53:213–223.
95.
Spalding, J. W., J. E. French, R. R. Tice, M. Furedi-Machacek, J. K. Haseman, and R. W. Tennant.1999. Development of a transgenic mouse model for carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol. Sci.49:241–254.
96.
Spalding, J. W., J. Momma, M. R. Elwell, and R. W. Tennant.1993. Chemically induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Ha-ras gene. Carcinogenesis14:1335–1341.
97.
Stoll, R., S. Furst, and J. Mennear.2001. Optimization of the Tg.AC transgenic mouse model: III. Effect of vehicle on responsiveness to dermal application of phorbol 12-myristate 13-acetate (TPA). Toxicologist60:278.
98.
Tabilio, A., P. G. Pelicci, G. Vinci, P. Mannoni, C. I. Civin, W. Vainchenker, U. Testa, M. Lipinski, H. Rochant, and J. Breton-Gorius.1983. Myeloid and megakaryocytic properties of K-562 cell lines. Cancer Res.43:4569–4574.
99.
Tennant, R. W., J. E. French, and J. W. Spalding.1995. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect.103:942–950.
100.
Tennant, R. W., J. Spalding, and J. E. French.1996. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res.365:119–127.
101.
Tennant, R. W., S. Stasiewicz, W. C. Eastin, J. Mennear, and J. W. Spalding.2001. The Tg.AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol. Pathol.29(suppl.):51–54.
102.
Tennant, R. W., S. Stasiewicz, J. Mennear, J. E. French, and J. W. Spalding.1999. Genetically altered mouse models for identifying carcinogens. In The use of short-and medium-term tests for carcinogens and data on genetic and related effects in carcinogenic hazard evaluation, ed. D. McGregor, J. Rice, and S. Venitt, 123–150, Lyon, France: IARC.
103.
Thompson, K. L., B. A. Rosenzweig, D. D. Broud, and F. D. Sistare.2001. Evaluation of the specificity of the Tg.AC assay by testing three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro. Toxicologist60:278.
104.
Thompson, K. L., B. A. Rosenzweig, R. Honchel, R. E. Cannon, R. E. Stoll, K. T. Blanchard, and F. D. Sistare. (In press). Chemically-induced skin papillomas in Tg.AC mice express transgene-derived mRNA but can lose the palindromic transgene promoter sequence required for initial responsiveness to tumorigens.
105.
Thompson, K. L., B. A. Rosenzweig, and F. D. Sistare.1998. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol. Pathol.26:548–555.
106.
Thompson, K. L., B. A. Rosenzweig, Y. Tsong, and F. D. Sistare.2000. Evaluation of in vitro reporter gene induction assays for use in a rapid prescreen for compound selection to test specificity in the Tg.AC mouse short-term carcinogenicity assay. Toxicol. Sci.57:43–53.
107.
Towatari, M., G. E. May, R. Marais, G. R. Perkins, C. J. Marshal, S. Cowley, and T. Enver.1995. Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3. J. Biol. Chem.270:4101–4107.
108.
Trempus, C. S., S. Ward, G. Farris, D. Malarkey, R. S. Faircloth, R. E. Cannon, and J. F. Mahler.1998. Association of v-Ha-ras transgene expression with development of erytholeukemia in Tg.AC transgenic mice. Am. J. Pathol.153:247–254.
109.
Ueda, Y., S. Hirai, S. Osada, A. Suzuki, K. Mizuno, and S. Ohno.1996. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem.271:23512–23519.
110.
van Birgelen, A. P. J., J. D. Johnson, A. F. Fuciarelli, J. D. Toft, M. Hejtmancik, J. Mahler, and J. R. Bucher.2000. Dermal and oral exposure of TCDD in Tg.AC mice: dose-and time-response studies. Toxicologist54:277.
111.
Wadkins, R. M.2000. Targeting DNA secondary structure. Curr. Med. Chem.7:1–15.
112.
Weitzman, S. A., and L. I. Gordon.1990. Inflammation and cancer: role of phagocyte generated oxidants in carcinogenesis. Blood76:655–663.
113.
Yoshida, H., and R. Fukunishi.1977. Mammary tumor and leukemia in male Sprague-Dawley rats evoked by a series of intragastric administration of 7,12-dimethylbenz(a)anthracene. Gann68:237–239.
114.
Zhang, Q., P. M. Reddy, C. Y. Yu, C. Bastiani, C. Higgs, G. Stamatoyannopoulos, T. Papayannopoulou, and C. K. Shen.1993. Transcriptional activation of human zeta 2 globin promoter by the alpha globin regulatory element (HS-40): functional role of specific nuclear factor-DNA complexes. Mol. Cell Biol.13:2298–2308.
